Anti-Cytochrome P450 1A1 antibody
| Name | Anti-Cytochrome P450 1A1 antibody |
|---|---|
| Supplier | Abcam |
| Catalog | ab3568 |
| Prices | $385.00 |
| Sizes | 100 µl |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Applications | IHC-P ICC/IF ICC/IF WB |
| Species Reactivities | Human |
| Antigen | Other Immunogen Type (His-tag) corresponding to Human Cytochrome P450 1A1 |
| Description | Rabbit Polyclonal |
| Gene | CYP1A1 |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
ab3568 at a dilution of 1/500 staining MCF-7 cell extract by Western blot.
ICC/IF image of ab3568 stained MCF7 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab3568, 1/1000 dilution) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
IHC image of ab3568 staining in Human breast carcinoma formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab3568, 1/200 dilution, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
HepG2 cells were incubated at 37°C for 24h with vehicle control (0 µM) and different concentrations of itraconazole (ab120816). Increased expression of cytochrome P450 1A1 (ab3568) in HepG2 cells correlates with an increase in nifuroxazide concentration, as described in literature.Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 3% milk before being incubated with ab3568 at 1/500 dilution and ab8227 at 1 µg/ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.
developed using the ECL techniquePerformed under reducing conditions.Exposure time : 16 minutesHepG2 cells were incubated at 37°C for 24h with vehicle control (0 µM) and 100 µM of fluconazole (ab141065). Increased expression of cytochrome P450 1A1 (ab3568) correlates with an increase in fluconazole concentration, as described in literature.Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 3% milk before being incubated with ab3568 at 1/500 dilution and ab8227 at 1 µg /ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.
Product References
Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits - Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits
Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT, Maitra A. Mol Cancer Ther. 2011 Aug;10(8):1470-80.
CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, - CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610,
Tan BS, Tiong KH, Muruhadas A, Randhawa N, Choo HL, Bradshaw TD, Stevens MF, Leong CO. Mol Cancer Ther. 2011 Oct;10(10):1982-92.